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ABSTRACT
IL-23 is a heterodimeric cytokine involved in inflammatory diseases; its role in 
cancer progression is controversial. Here we analyse the expression of IL-23 subunits 
(p40 and p19) and IL-23R in colorectal cancer with regard to disease progression, 
clinical-pathological and molecular aspects. Immunohistochemistry for IL-23p19, 
IL-23p40, IL-23R and CD8 was performed on a multi-punch tissue microarray of 
195 colorectal cancers (cohort 1), matched normal tissue, adenoma and lymph node 
metastases. Results were compared with clinical-pathological features and CD8+ 
T-cell counts, then validated on two patient cohorts (cohort 2: n=341, cohort 3: 
n=139). Cytoplasmic/membranous expression of IL-23 (p19 and p40 subunits) and 
IL-23R, respectively were over-expressed in carcinomas versus adenomas and normal 
tissues (p<0.0001) but were reduced in lymph node metastases (p<0.0001). Nuclear 
IL-23p19 expression was observed in 23.1% and was associated with early TNM stage 
(p=0.0186), absence of venous (p=0.0124) and lymphatic invasion (p=0.01493), 
favorable survival (p=0.014) and absence of distant metastasis (p=0.0146; specificity: 
100%). This unexpected cellular localization was confirmed by cell fractionation. The 
beneficial effect of nuclear IL-23p19 was restricted to tumours with CD8+ high counts. 
Results were validated on Cohorts 2/3. This multicenter study underlines the possible 
CD8+ dependency and beneficial effect of nuclear IL-23p19 on overall patient survival. 
INTRODUCTION
IL-23 is a heterodimeric cytokine and member of 
the interleukin 12 superfamily [1] composed of an IL-
23-specific subunit, IL-23p19 (IL-23A) and a subunit 
shared with IL-12 (IL-12p40). IL-23 is mainly secreted 
by activated dendritic cells and macrophages and plays 
an important role in mucosal immunology [2, 3]. It is 
widely known that IL-23 contributes to the progression 
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Table 1: Tissue microarray and clinicopathological data of included study cohorts
TMA characteristics Cohort 1 Cohort 2 Cohort 3
Origin: Greece Germany Switzerland
Total no. patients N=213 N=341 N=139
TMA Punch size 0.6mm 1.0mm 1.0mm
No. punches 4/tumor 1/tumor 1/tumor
Patients included from: 2002-2006 1993-2005 2002-2011
Surgical specimen/
Biopsy Surgery Surgery Preoperative biopsy
Clinicopathological features
Age (yrs) Mean (min, max) 68.4 (35, 93) 66 (25- 91) 70.2 (30-93)
Tumour size (cm) Mean (min, max) 4.6 (1, 12) - -
Gender Male 99 (48.3) 193 (56.6) 87 (63.0)
Female 106 (51.7) 148 (43.4) 51 (37.0)
Histological subtype Non-mucinous 181 (88.3) - 116 (86.6)
Mucinous 24 (11.7) 18 (13.4)
Tumour grade G1-2 130 (63.4) 225 (66.0) 81 (68.1)
G3 75 (36.6) 116 (34.0) 38 (31.9)
Tumour location Left 124 (60.5) 281 (82.4) 43 (31.4)
Rectum 27 (13.2) 0 (0.0) 39 (28.5)
Right 54 (26.3) 60 (17.6) 55 (40.2)
pT pT1+pT2 51 (24.9) 79 (23.2) 37 (26.8)
pT3+pT4 154 (75.1) 262 (76.8) 101 (73.2)
pN0 pN0 103 (50.2) 207 (60.9) 69 (50.0)
pN1-2 102 (49.8) 133 (39.1) 69 (50.0)
pM pM0 183 (89.3) 289 (84.8) 98 (73.1)*
pM1 22 (10.7) 52 (15.3) 36 (26.9)*
TNM stage Stage I 41 (21.8) 68 (20.0) 24 (17.9)
Stage II 53 (28.2) 127 (37.4) 34 (25.4)
Stage III 76 (40.4) 94 (27.7) 40 (29.9)
Stage IV 22 (9.6) 51 (15.0) 36 (26.9)
TNM staging ed. 6th 6th 7th
Tumour budding Low-grade 115 (55.3) - 71 (59.7)**
High-grade 93 (45.7) 48 (40.3)
Venous invasion Present 38 (18.1) - 64 (53.3)
Absent 172 (81.9) 56 (46.7)
Lymphatic invasion Present 84 (40.6) - 35 (29.9)
Absent 123 (59.4) 82 (70.1)
Post-operative therapy Untreated 76 (36.2) 209 (63.7) 108 (77.7)
Treated 134 (63.8) 119 (36.3) 31 (22.3)
Pre-operative therapy Untreated 210 (100%) 209 (100%) 117 (86.0)
Treated 0 (0%) 0 (0%) 19 (14.0)
MMR status Proficient 176 (91.7) 308 (90.3) 91 (85.1%)
Deficient 16 (8.3) 33 (9.7) 16 (15%)
KRAS status Wild-type 123 (65.1) - -
Mutation 66 (34.9)
BRAF status Wild-type 182 (90.1) - -
Mutation 20 (9.9)
CIMP status Negative/Low 94 (88.7) - -
High 12 (11.3)
Survival time Median (95%CI) 60 (48-65) 120 (100-NE) 101 (62-NE)
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of chronic inflammation by promoting the maturation and 
maintenance of T helper 17 cells (Th17) [4] and plays a 
pivotal role in the development of several autoimmune 
diseases like inflammatory bowel disease (IBD) [2], 
multiple sclerosis [5] and rheumatoid arthritis [6].
Recent evidence suggests that IL-23-mediated 
responses are important in the promotion of tumour 
progression in a variety of tissue types. IL-23 signalling 
through its receptor can occur through activation of the 
JAK/STAT pathway, specifically through STAT3 leading 
to upregulation of proteins linked to proliferation and 
survival (bcl-x), angiogenesis, metastasis (VEGF, HIF1α, 
MMP2, MMP9) and immunosuppression [7]. Expression 
of IL-23 mRNA, and specifically of subunit p19, is 
upregulated in a variety of cancer types such as ovarian 
cancers, head and neck cancers, lung, breast and stomach 
cancers as well as melanoma in comparison to matched 
normal tissue controls [8]. In vivo studies also support the 
pro-tumour effect of IL-23 and its receptor as underlined 
by work on knock-out mice (IL-23R-/- or IL-23p19-/-) 
showing marked growth-restriction in transplanted 
tumours and reductions in angiogenesis [8-10]. A recent 
study shows that ablation of IL-23 in polyp-prone mice 
leads to a significant reduction in the number of colorectal 
polyps [11]. Also reported is a marked upregulation of IL-
23 protein and mRNA in tumours from CPC-APC mice 
that develop cancers specifically in the colon. Grivennikov 
et al show diminished tumor multiplicity and growth with 
ablation of IL-23 or IL-23R in these mice [12].
On the other hand, anti-tumour and anti-metastatic 
properties of IL-23 have also been described. Lo and 
colleagues have shown that local production of IL-23 
inhibits metastatic colorectal tumour growth in vivo and 
that this anti-tumour activity requires CD8+ T-cells, but 
not CD4+ T-cells or NK cells [13]. 
The aim of this study was to determine the 
expression of IL-23 (p19 and p40) and IL-23R in the 
progression of colorectal cancers through the adenoma-
carcinoma-metastasis sequence, relationship to 
intratumoural CD8+ T-cells and impact on overall survival 
in patients with colorectal cancer.
RESULTS
Cohort 1
Differences in expression of IL-23R, IL-12p40, IL-
23 and nuclear IL-23p19 between tissue types 
In a first step, differences in expression of IL-23R, 
IL-12p40, IL-23 and nuclear IL-23p19 between normal 
tissues, adenomas, primary colorectal cancers and lymph 
node metastases were investigated (Supplemental Figure 
1). In all cases, there was a stepwise increase in expression 
from normal tissues to adenomas with the greatest 
expression in cancers (p<0.0001; all). Lymph nodes, on 
the other hand, showed a significantly lower expression in 
comparison to the primary tumour (p<0.0001; all). 
Association of IL-23R, IL-12p40, IL-23 and 
nuclear IL-23p19 with clinicopathological features 
and survival (Table 2)
Using Cohort 1, high expression of cytoplasmic 
and/or membranous staining was observed in 130/168 
(77.4%) for IL-23R, 111/185 (60%) for IL-12p40 and 
160/204 (78.4%) for IL-23 and was not associated with 
clinicopathological features or prognosis. In contrast, 
positive nuclear staining for IL-23p19 occurred in 
45 tumours (23.1%) and was significantly associated 
with a smaller tumour diameter (p=0.0333), early pT 
classification (p=0.0213), earlier TNM stage (p=0.0186), 
absence of vascular invasion (p=0.0124), and absence of 
lymphatic invasion (p=0.0493). Most strikingly, of the 
43 patients with IL-23p19 positivity, none had distant 
metastatic disease (p=0.0146). Sensitivity, specificity, 
positive predictive value (PPV) and negative predictive 
value (NPV) of IL-23p19 positivity for the absence of 
distant metastasis were 25.2%, 100%, 100%, and 12.3%.
Figure 1: Representative photomicrographs of positive/high (A, C, E, G) and negative/low expression (B, D, F, H) of A-B: 
IL-23 poly; C-D: IL-23p40; E-F: IL-23R and G -H: IL-23p19. 100 x magnification.
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Nuclear IL-23p19 and survival 
Positive expression of nuclear IL-23p19 had 
a significant and favorable effect on survival time, 
particularly at earlier time points. At 3-years, the overall 
survival rate was 87.5% (95%CI: 70-95) versus 64.7% 
(95%CI: 56-72) for negative patients (p=0.019). At 
4-years, IL-23p19 positive patients had a 70% (95%CI: 
28-91) overall survival rate in comparison to 55.6% 
(95%CI: 46-64) for negative patients (p=0.014). This 
effect on survival time was maintained in multivariable 
analysis with pT, pN and adjuvant therapy and indicated 
that the relative risk for patients with IL-23p19 positivity 
was 64% reduced in comparison to patients with IL-23p19 
negative tumours (p=0.0321). Additionally, the effect was 
also not influenced by mismatch repair (MMR) status 
(p=0.034; HR (95%CI): 0.43 (0.2-0.94)). At 5-years, 
survival difference was no longer observed (Figure 2A-B).
Association of IL-23p19, MMR, CIMP, KRAS 
and BRAF status
Molecular investigations of KRAS and BRAF 
revealed a 34.9% and 9.9% mutation rate, respectively. 
There was no association between IL-23p19 expression 
and KRAS or BRAF mutation. There was no association 
with high-level CIMP but a significantly larger number of 
nuclear IL-23p19 positive tumours were MMR-deficient 
(p=0.0032).
Figure 3: A) Kaplan-Meier survival curve of low and high CD8+ T-cell counts in patients not receiving a preoperative 
therapy (n=100). B) Kaplan-Meier curve showing combined nuclear IL-23p19 and CD8+ T-cell counts and effect on overall survival. 
Nuclear IL-23p19 positive/CD8+ high patients have a 100% survival. Effect of IL-23p19 negative/CD8+ high or IL23-p19 positive/CD8+ 
low has a more unfavorable intermediate effect while IL-23p19 negative/CD8+ low patients have the most limited benefit. C) Multivariable 
analysis showing the independent prognostic effect of the combined IL-23p19 positive/CD8+ effects on overall survival.
Figure 2: Cohort 3 A) Kaplan-Meier survival curve of test cohort showing survival time benefit of nuclear IL-23p19 positive patients 
particularly at early time points and B) a multivariable analysis of this cohort at 4-years follow-up. Stratification by CD8+ T-cell counts 
shows C) survival time benefit in patients with nuclear IL-23p19 positive cancers in CD8+ high setting with D) no benefit in CD8+ low 
setting.
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Figure 4: Immunoblot showing both nuclear and 
cytoplasmic fractions for IL-23p19 (IL-23A) and 
appropriate controls.
Table 2: Association of nuclear IL-23p19 expression with clinicopathological data of Cohort 1
Feature Total (n=213) IL-23p19 N (%) (n=195) P-value
Negative
 (n=150; 76.9%)
Positive
(n=45; 23.1%)
Age (yrs) Mean (min, max) 68.4 (35, 93) 68.2 (35, 93) 70.1 (41, 91) 0.2468
Tumour size (cm) Mean (min, max) 4.6 (1, 12) 4.8 (1, 12) 4.1 (1.2, 8.0) 0.0333
Gender Male 99 (48.3) 69 (47.6) 21 (47.7) 0.9869
Female 106 (51.7) 76 (52.4) 23 (52.3)
Histological subtype Non-mucinous 181 (88.3) 128 (88.3) 41 (93.2) 0.5753
Mucinous 24 (11.7) 17 (11.7) 3 (6.8)
Tumour grade G1-2 130 (63.4) 89 (61.4) 32 (72.7) 0.1695
G3 75 (36.6) 56 (38.6) 12 (27.3)
Tumour location Left 124 (60.5) 87 (60.0) 22 (50.0) 0.4056
Rectum 27 (13.2) 20 (13.8) 6 (13.6)
Right 54 (26.3) 38 (26.2) 16 (36.4)
pT pT1+pT2 51 (24.9) 31 (21.4) 17 (38.6) 0.0213
pT3+pT4 154 (75.1) 114 (78.6) 27 (61.4)
pN0 pN0 103 (50.2) 69 (47.6) 28 (63.6) 0.0621
pN1-2 102 (49.8) 76 (52.4) 16 (36.4)
pM pM0 183 (89.3) 128 (87.7) 43 (100.0) 0.0146
pM1 22 (10.7) 18 (12.3) 0 (0.0)
TNM stage Stage I 41 (21.8) 26 (17.3) 15 (33.3) 0.0186
Stage II 53 (28.2) 40 (26.7) 13 (28.9)
Stage III 76 (40.4) 61 (40.7) 15 (33.3)
Stage IV 22 (9.6) 18 (12.4) 0 (0.0)
Tumour budding Low-grade 115 (55.3) 80 (54.8) 27 (60.0) 0.5385
High-grade 93 (4.7) 66 (45.2) 18 (40.0)
Venous invasion Present 38 (18.1) 30 (20.3) 2 (4.4) 0.0124
Absent 172 (81.9) 118 (79.7) 43 (95.6)
Lymphatic invasion Present 84 (40.6) 64 (43.8) 12 (27.3) 0.0493
Absent 123 (59.4) 82 (56.2) 32 (72.7)
Therapy Untreated 76 (36.2) 49 (33.3) 22 (48.9) 0.0586
Treated 134 (63.8) 98 (66.7) 23 (51.1)
MMR status Proficient 176 (91.7) 140 (95.2) 36 (80.0) 0.0032
Deficient 16 (8.3) 7 (4.8) 9 (20.0)
KRAS status Wild-type 123 (65.1) 86 (65.2) 24 (60.0) 0.5522
Mutation 66 (34.9) 46 (34.9) 16 (40.0)
BRAF status Wild-type 182 (90.1) 126 (90.0) 40 (88.9) 0.7835
Mutation 20 (9.9) 14 (10.0) 5 (11.1)
CIMP status Negative/Low 94 (88.7) 77 (90.6) 17 (81.0) 0.249
High 12 (11.3) 8 (9.4) 4 (19.1)
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Effect of nuclear IL-23p19 is dependent on the 
presence of CD8+ T-lymphocytes
There was no correlation between CD8+ 
T-lymphocytes and nuclear IL-23p19 expression. Since the 
effect of IL-23 on tumour growth restriction has previously 
been reported to depend on CD8+ T-lymphocytes [8], 
we stratified the cohort by total CD8+ counts using the 
median value. There were 96 patients in the CD8+ T-cell 
low group and 98 patients in the CD8+ T-cell high group. 
The associations between IL-23p19 nuclear staining 
and favorable prognostic features were exclusively 
maintained in the CD8+ T-cell high group (Table 3), 
namely with smaller tumour diameter (p=0.0001), earlier 
pT stage (p=0.022), lymph node negativity (p=0.0274), 
Table 3: Nuclear IL-23p19 in cohort 1 stratified by CD8+ low and high groups
Feature CD8+ low (Freq N %) P CD8+ high (Freq N %) P
Negative
(n=82)
Positive
(n=14)
Negative
(n=80)
Positive
(n=18)
Age (yrs) Mean (range) 68.1 (36-91) 69.8 (41-83) 0.4168 68.9 (35-93) 68.2 (46-81) 0.7422
Tumour size (cm) Mean (range) 4.8 (1-12) 5.0 (2.2-8.0) 0.6276 4.8 (1.2-9.0) 3.1 (1.2-6.0) 0.0001
Gender Male 38 (48.1) 6 (42.9) 0.7172 38 (49.4) 7 (38.9) 0.4235
Female 41 (51.9) 8 (57.1) 39 (50.7) 11 (61.1)
Histological 
subtype Non-mucinous 71 (91.0) 13 (92.9) 1.0 68 (87.2) 16 (88.9) 1.0
Mucinous 7 (9.0) 1 (7.1) 10 (12.8) 2 (11.1)
Tumour grade G1-2 48 (61.5) 9 (64.3) 0.8454 49 (62.8) 15 (83.3) 0.0961
G3 30 (38.5) 5 (35.7) 29 (37.2) 3 (16.7)
Tumour location Left 42 (53.9) 9 (64.3) 0.3591 51 (65.4) 7 (38.9) 0.1015
Rectum 10 (12.8) 0 (0.0) 12 (15.4) 4 (22.2)
Right 26 (33.3) 5 (35.7) 15 (19.2) 7 (38.9)
pT pT1+pT2 17 (21.8) 4 (28.6) 0.7297 18 (23.1) 9 (50.0) 0.022
pT3+pT4 61 (78.2) 10 (71.4) 60 (76.9) 9 (50.0)
pN0 pN0 33 (42.3) 6 (42.9) 0.9694 43 (55.1) 15 (83.3) 0.0274
pN1-2 45 (57.7) 8 (57.1) 35 (44.9) 3 (16.7)
pM pM0 67 (84.8) 14 (100.0) 0.2017 72 (92.3) 17 (100.0) 0.2371
pM1 12 (15.2) 0 (0.0) 6 (7.7) 0 (0.0)
TNM stage Stage I 3 (3.9) 2 (14.3) 0.4088 2 (2.6) 5 (27.8) 0.0017
Stage II 14 (18.0) 2 (14.3) 16 (20.2) 4 (22.2)
Stage III 48 (61.5) 7 (50.0) 43 (55.1) (44.4)
Stage IV 13 (16.7) 3 (21.4) 17 (21.8) 1 (5.6)
Tumour budding Low-grade 41 (51.3) 9 (64.3) 0.3672 46 (59.0) 11 (61.1) 1.0
High-grade 39 (48.8) 5 (35.7) 32 (41.0) 7 (39.0)
Venous invasion Present 20 (24.7) 1 (7.1) 0.144 11 (13.9) 0 (0.0) 0.0927
Absent 61 (75.3) 13 (92.9) 68 (86.1) 18 (100.0)
Lymphatic invasion Present 38 (48.1) 6 (42.9) 0.7172 29 (37.2) 2 (11.1) 0.033
Absent 41 (51.9) 8 (57.1) 49 (62.8) 16 (88.9)
Therapy Untreated 18 (22.2) 6 (42.9) 0.1787 34 (43.6) 12 (66.7) 0.0773
Treated 63 (77.8) 8 (57.1) 44 (56.4) 6 (33.3)
MMR status Proficient 76 (95.0) 9 (64.3) 0.0003 75 (94.9) 15 (83.3) 0.1164
Deficient 4 (5.0) 5 (53.7) 4 (5.1) 3 (16.7)
KRAS status Wild-type 40 (56.3) 8 (61.5) 0.7708 52 (71.2) 9 (64.3) 0.7507
Mutation 31 (43.7) 5 (38.5) 21 (28.8) 5 (35.7)
BRAF status Wild-type 70 (92.1) 13 (92.9) 1.0 67 (88.2) 15 (83.3) 0.6942
Mutation 6 (7.9) 1 (7.1) 9 (11.8) 3 (16.7)
CIMP status Negative/Low 39 (88.6) 9 (90.0) 0.9014 38 (82.7) 8 (72.7) 0.1006
High 5 (11.4) 1 (10.0) 3 (7.3) 3 (27.3)
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earlier TNM stage (p=0.0017) and absence of lymphatic 
invasion (p=0.033). Although not reaching statistical 
significance, all IL-23p19 nuclear positive cases (n=17) 
were free of distant metastasis. Overall survival time was 
also prolonged in patients with nuclear IL-23p19 positivity 
(100% survival) in the CD8+ T-cell high group (p=0.0771) 
(Figure 2 C-D) with no effect in the CD8+ T-cell low 
group (p=0.3895).
Validation study 
Cohort 2: Frequency and prognostic impact of 
nuclear IL-23p19 expression
Nuclear IL-23p19 positivity was identified in 46/341 
(13.5%) of cases and was significantly associated with a 
longer follow-up time (p=0.0116). A tendency toward 
an earlier TNM stage (p=0.0977) was observed. Most 
importantly, of the 46 tumours with IL-23p19 positivity, 
only 3 had metastatic disease in comparison to 49 of the 
295 negative patients (p=0.0529). Sensitivity, specificity, 
PPV and NPV of IL-23p19 for distant metastasis were 
14.9%, 94.2%, 93.4%, and 16.6%, respectively. Survival 
time in patients with nuclear IL-23p19 positivity was 
considerably longer in comparison to IL-23p19 negative 
patients, but did not reach significance. However, a 
subgroup analysis of patients by TNM stage revealed 
a significant benefit in patients with stage III disease 
(p=0.0363) (Supplemental Figure 2). This association 
was also maintained in multivariable analysis with 
adjuvant therapy (p=0.0413; HR (95%CI): 0.29 (0.1-
0.9)). Moreover, of these patients, 10 were MMR-
deficient. There was no association between IL-23p19 
and MMR status. Adjusting the multivariable analysis for 
MMR status, again IL-23p19 positivity had a significant 
beneficial effect on overall survival (p=0.0446; HR 
(95%CI: 0.35 (0.12-0.98)).
Cohort 3: Impact on survival stratified by CD8+ 
T-lymphocytes
Nuclear IL-23p19 positivity was identified in 22/139 
(15.8%) of cases. There was no association of expression 
with clinicopathological features. Evaluating only patients 
who did not receive any preoperative therapy (n=117), 
survival time analysis showed a marked favorable survival 
time in patients expressing nuclear IL-23p19 but this 
result did not reach statistical significance (p=0.1536). 
Cases were then stratified into low and high intraepithelial 
CD8+ T-cell counts (median value as threshold: 3.4 cells). 
Evaluating only patients with both CD8+ T-cell counts 
and IL-23p19 counts (n=100), a beneficial effect of IL-
23p19 positivity on overall survival appears limited to the 
CD8+ high group (Supplemental Figure 2). This effect is 
underlined when evaluating the combination of IL-23p19 
and CD8+ groups (p=0.0195). A clear additive effect 
of IL-23p19 to CD8+ T-cell counts can be observed by 
comparing Figures 3A and 3B. 5-year overall survival for 
patients with both IL-23p19 nuclear expression and CD8+ 
high counts was 100% in comparison to those with IL-
23p19 negative and CD8+ low counts (39.2% (95%CI: 
21-57)) and 70% (95%CI: 53-82) for patients with either 
IL-23p19 negative/CD8+ high or IL-23p19 positive/
CD8+ low counts (Figure 3B). This effect could even 
be maintained in multivariable analysis with pT, pN and 
adjuvant therapy (Figure 3C). Additionally, information 
on MMR status was available for 93 of these patients and 
15/93 (16.1%) were identified as MMR-deficient. Of these 
15 patients, 3 were positive for nuclear IL-23p19 and 12 
negative (p=0.7177). Not only did multivariable analysis 
of the combined expression IL-23p19/CD8+ with MMR 
status maintain its statistical significance (HR (95%CI: 
0.39 (0.2-0.73); p=0.0035)), but subgroup analysis also 
showed similar survival times after removal of –deficient 
cases (p=0.0155). 
Cell fractionation and confirmation of nuclear 
expression
In order to confirm the localization of expression 
of IL-23p19, a myc-tagged IL-23p19 expression plasmid 
was used. Figure 4 shows the localization of the IL23p19 
protein in both cytoplasmic and nuclear fractions 
with both localizations producing strong bands upon 
immunoblotting. 
DISCUSSION
In this study we could demonstrate that a) IL-23 
signalling may be involved in the early, rather than late, 
progression of colorectal cancer, b) nuclear expression of 
IL-23p19 is a marker of early disease and c) the beneficial 
prognostic impact of nuclear IL-23p19 may be restricted 
to patients with high anti-tumour T-cell responses. This 
was accomplished by first investigating IL-23p19, IL-
23p40 and IL-23R in normal colonic tissue, matched 
adenomas, carcinomas and lymph node metastases from 
a well-characterized cohort of colorectal cancer patients. 
Then a total of 675 patients from three independent 
institutions were analysed and correlated with overall 
survival and CD8+ T-cell counts. 
Our findings underline an increased expression of 
IL-23p19, IL-23p40 and IL-23R in the normal-adenoma-
carcinoma sequence followed by a marked reduction in 
expression in lymph node metastases. This result supports 
the notion that IL-23 and its receptor may be required for 
early colorectal tumourigenesis rather than for metastatic 
dissemination. This result is further supported by the 
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association of nuclear IL-23p19 with early TNM stage, 
favourable survival time and the notable absence of distant 
metastatic disease. Our results are in line with Trinchieri 
and colleagues who showed a significant upregulation of 
IL-23 mRNA (p19 and p40) in various cancer tissues in 
comparison to their adjacent normal tissue counterpart 
[20]. Langowski et al found similar results highlighting 
an increased IL-23p19 gene expression in colon cancers in 
comparison to normal tissues [8]. Recently, Grivennikov 
and co-workers found an upregulation of IL-23 in 
mouse colon tumours in comparison to matched non-
tumour colons [12]. Others have shown increased IL-
23 levels in the serum of colorectal cancer patients in 
comparison to healthy controls [21]. Interesting is also 
the apparent change of expression of IL-23p19 from a 
more cytoplasmic to nuclear localisation with progression 
from adenomas to carcinoma. While such a change in 
protein expression by cellular localisation is not unusual 
(e.g. β-catenin), it may be congruent here with a change 
in the inflammatory response. Our study using matched 
normal-adenoma-carcinoma and lymph node metastases 
underlines the possible role of IL-23/IL-23R in the early, 
rather than late progression of colorectal cancers.
Although our results point to a beneficial impact of 
IL-23p19 on patient outcome, controversial and opposing 
roles of IL-23 have been previously described. On the one 
hand, Langowski and colleagues show that IL-23-receptor-
deficient mice show an impressive growth-restriction 
in transplanted tumours. Moreover, the expression of 
MMP9, a marker of tumour-angiogenesis is significantly 
decreased in IL-23p19-/- mice [8]. On the other hand, 
several studies point toward a role for IL-23 in enhanced 
anti-tumour immunity. Lo and colleagues show that local 
IL-23 secretion reduces tumourigenicity and metastasis, 
promotes growth retardation and prolongs survival in a 
mouse model [13]. Mice over-expressing IL-23 were 
found to secrete large amounts of IFNγ, suggesting the 
involvement of T-cells, leading to systemic anti-tumour 
immunity [22]. This was further supported by work by 
Shan et al. showing that IL-23 secreted by tumour cells 
could enhance CTL activity and the production of Th1 
cytokines such as IFNγ, IL-12 and TNF-α [23]. 
In our study, we show that the beneficial prognostic 
effect of nuclear IL-23p19 on overall survival may be 
restricted to tumours with high CD8+ T-cell counts. 
Possibly, IL-23 could induce an enhancement of 
CD8 activity, shifting the balance within the tumour 
microenvironment towards an anti-tumourous milieu 
[23, 24]. This finding is underlined by the more frequent 
IL-23p19 positivity in tumours with MMR-deficiency, a 
subgroup of colorectal cancers known for their abundant 
CD8+ T-cell counts and favourable survival in affected 
patients. Our finding is in agreement with previous in 
vivo experiments investigating effects of injection of IL-
23p19 over-expressed colon cancer cell lines into either 
immune-competent or -deficient mice. In BALB/c mice, 
IL-23p19 over-expression in cell lines and injection led 
to a significantly lower tumour volume in comparison 
to control [22]. When these mice were treated with anti-
CD8 antibody, this effect was compromised [13]. In 
SCID (deficient in B and T cells) or SCID/beige mice 
(deficient in B, T and NK cells), no difference in effects 
was observed with or without IL-23p19 over-expression. 
These results suggest that the anti-tumour properties of 
IL-23p19 may be found in tumours with abundant CD8+ 
T-cell counts. In our study, the beneficial effects of nuclear 
IL-23p19 on overall patient survival are also generally 
restricted to patients with high CD8+ T-cell numbers. In 
fact, although CD8+ T-cell counts alone have been shown 
to have an excellent prognostic impact [18], an additive 
effect leading to improved stratification of patients with 
nuclear IL-23p19 positivity among those with high CD8+ 
T-cell counts is highlighted in this study.
It is known that several molecular features in 
colorectal cancers may have an influence of the immune 
response. In the case of MMR-deficiency, colorectal 
cancers often show an inherent abundance of CD8+ 
T-cells. These tumors which are microsatellite instable 
are often BRAF mutated and show a high-level CIMP, 
but rarely KRAS mutations [25]. Because of its role in 
immunity, these molecular features were evaluated in the 
context of IL-23 to ensure no confounding of our results. 
A recent work by Petanidis and colleagues showed that 
inhibition of KRAS using manumycin A could cause 
a significant decrease in IL-23 levels establishing a 
correlation between these two molecules [26]. We found 
no association between IL-23p19, and these molecular 
changes. This is similar to Grivennikov and colleagues 
who report an upregulation of IL-23 in early cancers but 
no further increase in expression in more advanced mouse 
colorectal cancers caused by Apc loss and forced KRAS 
or BRAF activation [12]. 
Nuclear expression of IL-23p19 using a monoclonal 
antibody was found in 13-23% of all patients. This 
unexpected nuclear localisation was nonetheless confirmed 
after cell fractionation that showed both cytoplasmic 
and nuclear expression. The result is consistent with 
the findings using both the polyclonal (IL-23) and 
monoclonal (IL-23p19) antibodies targeting this protein 
by immunohistochemistry. The function, however, of 
IL-23p19 in the nucleus remains to be elucidated. Since 
cytokines secreted outside of their original compartment 
can no longer be observed by immunohistochemistry, 
the observation of nuclear localisation does not preclude 
stimulation of other cell types after secretion. In this 
study, we tested the clinical relevance of IL-23p19 nuclear 
expression in 675 patients from three different countries 
(Greece, Germany and Switzerland). Interestingly, 
consistent survival results were found, suggesting that 
the biological behaviour of the tumours may, in this 
case, be more relevant to patient outcome than standard 
surgery. These results could furthermore be found using 
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multiple- or single punch tissue microarrays and also using 
material from resection specimens and also biopsies. Some 
limitation may nonetheless include the limited availability 
of some clinical/pathological features in the validation 
cohorts including. 
In conclusion, IL-23 and IL-23R may play a role 
in early colorectal cancer progression. However, among 
patients with cancer, nuclear expression of IL-23p19 
is an advantageous prognostic factor with an apparent 
‘protective’ function that may be CD8+ dependent. 
Additional studies are required to confirm these findings 
in colorectal cancer patients and to further elucidate the 
role of IL-23p19 in tumour cells and link to anti-tumour 
immunity.
MATERIALS AND METHODS
Patients
Clinicopathological data of all patient cohorts can 
be found in Table 1.
Cohort 1 (Test cohort)
A retrospective study cohort of 220 non-consecutive 
patients with primary resected colorectal cancers treated 
at the Fourth Department of Surgery, University of Athens 
Medical School in Athens, Greece, between 2002 and 
2006 was entered into this study. Clinicopathological 
data were reviewed from patient charts and included age 
at diagnosis, gender, tumour location, the histological 
subtype of the tumour, tumour grade, TNM stage (UICC 
6th ed.), and the presence of lymphatic and vascular 
invasion. Additionally, tumour budding at the invasion 
front was assessed using a 10 in 10 method and classified 
into high-grade and low-grade [14]. None of the patients 
received pre-operative therapy. No patient had IBD-
associated colorectal cancers. Information on post-
operative therapy was available for 210 patients. Median 
survival time was 60 months (95%CI: 48-65). The clinical 
endpoint of interest was distant metastasis and overall 
survival. Permission has been granted by the local ethics 
committee of the University of Athens.
Cohort 2 (Validation cohort on resection 
specimens)
In order to validate important results from the test 
cohort, a second cohort consisting of 341 primary resected 
colon cancer (no rectal cancer) patients treated at the 
Department of Surgery at the Technical University Munich 
hospital, Munich, Germany, between 1993 and 2005 was 
used. Clinical and pathological features for this cohort 
included age at diagnosis, gender, tumour location, TNM 
stage (UICC 6th ed), R classification, and tumour grade. 
Information on post-operative therapy was available 
in 328 cases. Seven patients had an IBD-associated 
colorectal cancer. Median survival time for the cohort was 
120 (95%CI: 100-NE) months. The clinical endpoint of 
interest was distant metastasis and overall survival. The 
ethics committee of the Klinikum rechts der Isar approved 
the study (no. 1926/7). All samples were obtained after 
prior informed written consent.
Cohort 3 (Validation cohort on preoperative 
biopsies)
Next, in order to validate findings from cohorts 1 
and 2 on a third independent patient sample this time using 
preoperative colorectal cancer biopsies, we identified 139 
patients with both biopsy and matched colorectal cancer 
resection treated from 2002-2011 at the Bern University 
Hospital (Bern, Switzerland). All Haematoxylin and Eosin 
(HE) slides from surgical resections were re-reviewed. 
Information on age at diagnosis, gender, tumour location, 
tumour grade, and TNM (UICC 7th ed.) was recorded. 
Nineteen patients received a pre-operative therapy. 
No patients had an IBD-associated colorectal cancer. 
Information on post-operative therapy and survival time 
was available. Median survival time was 101 (95%CI: 
62-NE) months. Clinical endpoint of interest was overall 
survival. Permission has been granted by the local ethics 
committee (Registration: 07-10-13).
Assay Methods
Tissue microarray
Tissue microarrays were used for evaluation of 
protein expression. For Cohort 1, a multiple-punch tissue 
microarray of 0.6mm diameter cores was investigated. 
On average 4 tumour punches were obtained per case 
including 2 from the tumour center and 2 from the 
invasion front [15]. Single tissue punches of 54 adenomas, 
151 normal tissues and 88 tumour infiltrated lymph nodes 
were also included. The complete array contained 1283 
tissue spots. For the Cohort 2, a single-punch tissue 
microarray of 1.0mm diameter cores per colon cancer 
was evaluated [16]. For Cohort 3, a single-punch tissue 
microarray of 1.0mm in diameter was constructed based 
on preoperative biopsy material [17].
Immunohistochemistry
A multi-tissue test microarray containing 280 tissue 
spots from matched neoplastic and non-neoplastic tissues 
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from different tissue types and organs was initially used 
for antibody testing and validation. This tissue microarray 
was cut at 4µm and underwent immunohistochemistry 
using an automated immunostainer (Leica, Bond III) for 
the following antibodies: IL-23R (Abcam, goat polyclonal, 
citrate 30’, 100°, 1:100), IL-12p40 (aka IL-12B, Abcam, 
rabbit polyclonal, Tris 30’, 95°, 1:2500), IL-23 (aka 
IL-23p19, Abcam, rabbit polyclonal, no pretreatment, 
1:200) and IL-23p19 (Abcam, mouse monoclonal, 
clone HLT 2736, enzyme pretreatment, 1:25). Next, the 
tissue microarray for the Cohort 1 was similarly cut and 
immunostaining performed for all antibodies. Additional 
staining for CD8+ (Abcam, Tris 20’ 95°, 1:100) was 
performed on the Cohort 1 and Cohort 3 [17].
Evaluation of immunohistochemistry
For evaluation of immunohistochemistry, only 
epithelial cells were scored. Membranous and/or 
cytoplasmic immunoreactivity was noted for IL-23R, 
IL-12p40, and IL-23. In addition, nuclear staining was 
observed for IL-23 using the monoclonal antibody (IL-
23p19). For the normal tissue, adenoma and lymph 
node, the percentage of positive cells was denoted. 
The percentage of positive IL-23 cells per punch was 
investigated and then the average expression across the 
multiple cores was assigned per patient. Then, using 
receiver operating characteristic (ROC) curve analysis, 
each patient was assigned a negative and positive scores 
based on the identified threshold value. For IL-23R, IL-
12p40 and IL-23, this threshold was 95% (low expression 
<95%, full expression ≥95% tumour cell staining). Nuclear 
staining of IL-23p19 was classified as negative (0%) or 
positive (any staining). Representative immunostains are 
shown in Figure 1. Although this study focused on cancer 
cell expression of these markers, stromal cell staining was 
observed for IL-12p40, IL-23R and IL-23 (polyclonal 
antibody). Only very infrequent expression of nuclear IL-
23p19 was observed in dendritic cells in colorectal cancers 
and was considered too rare to be evaluated separately. 
CD8+ staining was evaluated on whole tissue sections 
from biopsies in cohort 3 in 5 HPFs as found in [17] 
and the average across the 5 fields used for analysis. For 
Cohort 1, intraepithelial and stromal counts of CD8+ were 
made per punch, pooled and then averaged across each 
tumour [18]. For Cohort 3, only intraepithelial counts were 
made, since these were found on the same patient cohort to 
have the greatest prognostic significance [17]. 
Molecular analysis
Since the molecular background of colorectal 
cancers may influence the immune response, analysis 
of KRAS and BRAF mutations, as well as CpG Island 
Methylator Phenotype (CIMP) were carried out. Detailed 
protocols and primer sequences can be found in [19]. 
Briefly, mutation analysis by pyrosequencing for BRAF 
(exon 15, V600E mutations) and KRAS (exon 2, codon 12 
and 13) was performed. For CpG methylation analysis, 
bisulfite conversion of all DNA samples was undertaken 
using the EpiTect Bisulfite Conversion Kit (Qiagen) 
according to manufacturer’s instructions. CpG analysis 
for SOCS1, NEUROG1, MLH1, CRABP1A, CDKN2A, and 
RUNX3 were also carried out. Following PCR, fragment 
analysis was carried out using the QIAxcel system 
(Qiagen). Bisulfite controls were included into the program 
for each assay manually to ensure complete conversion 
of DNA. For each assay, the ratio of C:T indicating the 
percentage of methylated to non-methylated C residues at 
each CpG site was noted. Then an average percentage of 
methylation across each case was determined. For each 
gene, the 75th-percentile was used as a cutoff to determine 
“hypermethylation” status. CIMP-high was defined by at 
least 3/6 hypermethylated genes, CIMP-low as at most 
2/6 hypermethylated genes and CIMP-negative as 0/6 
hypermethylated genes. 
Expression plasmids and transient transfection
A myc-tagged IL-23p19 (IL-23A) pCMV6 
expression plasmid was purchased from Origene 
(Labforce, Nunningen, Switzerland) and 4 µG of this 
plasmid were transfected into 293T HEK cells using 
calcium phosphate technique. 
Cellular fractionation and immunoblotting
Cytoplasmic and nuclear fractionation was achieved 
by first lysing the cells in buffer A (HEPES 10 mM 
(pH 8.0), KCl 10 mM, MgCl2 1.5 mM, DTT 1mM), 
centrifugation and recovering the supernatant. The cell 
pellet was re-suspended in buffer B (HEPES 20 mM (pH 
8.0), MgCl2 1.5 mM, KCl 400 mM, NaCl 40 mM, EDTA 
0.2 mM, DTT 1 mM, glycerol 25%) to lyse the nuclear 
envelope and nuclear proteins were extracted. Protein 
content was determined by a Bradford Assay (#500-0006; 
Bio-Rad) with BSA as a standard. 5µg of cytoplasmic 
and nuclear protein was analysed by electrophoresis 
on a mini protean TGX Precast gel (Bio-Rad). Primary 
antibodies used were anti-Myc-tag (AB13836; Abcam), 
anti-α-Tubulin (#3873; Cell Signaling) and anti-Histone 
H3 (06-599; Millipore). Secondary antibodies used were 
anti-rabbit and anti-mouse IgG HRP-linked (NA93IV; 
GE Healthcare). Chemiluminescence signal was detected 
using an ECL-kit (170-5060; Bio-Rad).
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Statistical Analysis
Differences in expression between tissue types were 
investigated using the Friedman test for matched samples 
and Kruskal-Wallis test. Differences in expression and 
association with categorical clinicopathological features 
were analysed with the Chi-Square or Fisher’s Exact 
test, where appropriate. For patient age and tumour 
diameter, the Wilcoxon Rank Sum Test was used. Kaplan-
Meier curves were plotted and survival time differences 
assessed using the log-rank test. Multivariable analysis 
was performed by including possible confounders and 
post-operative therapy in addition to the protein marker of 
interest into a Cox regression analysis. Hazard ratios (HR) 
and 95% confidence intervals (CI) were used to determine 
the effect of each variable on overall survival. The 
sensitivity, specificity, positive and negative predictive 
values (PPV, NPV) of the expression for distant metastasis 
were identified. Correlations with CD8 were made using 
the Spearman Rank correlation coefficients. All p-values 
were two-sided and considered significant when p<0.05. 
Analyses were performed using SAS (V9.2, The SAS 
Institute, Cary, NC).
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